Enamine Ltd.
23 Alexandra Matrosova Street
Kiev
01103
Tel: 380-44-537-3218
Fax: 380-44-537-3253
Website: http://www.enamine.net/
Email: enamine@enamine.net
About Enamine Ltd.
Enamine is one of the top providers of custom chemistry services and screening libraries for pre-clinical drug discovery and agro chemistry worldwide. Currently Enamine offers one of the largest and most diverse proprietary screening collections of small organic compounds in the world.
Enamine supplies following products from in house stock:
- screening Compounds (over 900,000 items);
- proprietary Building Blocks (over 19,000 items).
We offer prompt resupply and resynthesis of compounds from our collection. Compounds can be formatted in different ways to meet our customers’ needs. Enamine carries out total Quality Control by LC/MS and NMR.
Enamine also offers synthesis of compounds from immediately accessible, validated chemical space (REAL DataBase) of over 11 million structures and warrants the timely delivery of a minimum of 60% of the compounds selected from this database. Cherry-picking is always welcomed and compounds can be prepared on exclusive basis.
Enamine has earned a reputation as a leading provider of a number of chemistry services, including custom synthesis and lead optimization services. Keeping close ties with Ukrainian academic research centers, Enamine has expertise in a variety of contemporary organic chemistry fields, such as asymmetric synthesis, synthesis of structurally rigid and caged amino acid derivatives, synthesis of fluorescent dyes, and peptidomimetics. We also support other projects aimed at the development of fundamental research in organic chemistry. Enamine scientific expertise is supported by published articles in respected international journals.
The molecular modeling department of Enamine is capable of performing complex computation tasks associated with computer aided drug design, from ADME properties prediction and database profiling to lead optimization and design of focused and targeted libraries for biologically significant targets.
At Enamine, we are committed to providing life science industries with a full spectrum of hit-to-lead discovery services. Our competitive pricing policy, top-level customer support and highest quality standards makes Enamine an ideal partner for your outsourcing needs.
Last Updated: 12-11-2007
30 articles about Enamine Ltd.
-
SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery
1/11/2024
SyntheticGestalt and Enamine have announced the start of a joint effort to create a suite of AI models that will enable the generation of synthetically accessible biologically active compounds with optimized physicochemical and ADME/ Tox properties.
-
Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration
4/19/2023
Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused on the development of endogenous regenerative medicines.
-
Three months after the invasion began, Yurii Moroz, the executive director of Kyiv-based Chemspace LLC, has returned to his offices to restart operations.
-
The crisis caused by the shutdown of one plant is a stark reminder of critical supply chain issues in other sectors, including the pharmaceutical industry.
-
Russia’s continued assault on Ukraine threatens a supply of chemicals and compounds that drug researchers and developers use across the globe.
-
The Russian invasion of Ukraine has hampered Ukrainian research to develop new treatments for infection from the SARS-CoV-2 virus and increased the risk of spreading virulent pathogens.
-
Andrey Tolmachov issued a letter to the global drug discovery and scientific community, underscoring the importance of condemnation and action against Russian invasion.
-
Enamine Extend Collaboration With Prominent Swiss Biotech
2/24/2021
Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced that it has extended its long-standing research collaboration with Addex Therapeutics Ltd, a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development.
-
Optibrium collaborates with Enamine and BioSolveIT to add REAL Space Search Tool to StarDrop
11/19/2019
New extension enables researchers to explore the REAL Space of 11 billion readily accessible compounds directly from StarDrop
-
Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design
11/5/2019
At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.
-
Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen
6/24/2019
Atomwise, Enamine, and top university researchers collaborate to discover novel small molecules for the treatment of pediatric cancers using the power of AI and novel chemistry.
-
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
-
Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck
3/26/2019
Enamine Ltd. and H. Lundbeck A/S announced the expansion of their research collaboration.
-
Optibrium and Enamine collaboration extends commercial compound database access for StarDrop users
9/10/2018
Partnership expands number of free extensions available through StarDrop
-
Enamine and BioSolveIT Launch the World's Largest Searchable Chemical Space for Novel Compound Sourcing
2/8/2018
Enamine and BioSolveIT announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world's largest chemical space of commercially accessible compounds.
-
Enamine Expands Collaboration with UCSF to Explore Synthetically Feasible Chemical Space
1/25/2018
Enamine today announced that it has expanded its collaboration on ZINC, a comprehensive online database of purchasable compounds curated by the Irwin and Shoichet laboratories in the Department of Pharmaceutical Chemistry at the University of California, San Francisco (UCSF).
-
Enamine Supplies DSI Poised Fragment and Analogue Libraries to Diamond Light Source XChem Facility and SGC Oxford Screening Efforts
1/10/2018
Diamond Light Source (Diamond) and the Structural Genomic Consortium (SGC) Oxford announced today that Enamine, a chemical company and producer of novel chemical building blocks and screening libraries, will become a key supplier of poised fragment and analogue libraries to its XChem facility. Enamine will offer a new generation of the hit-finding library, Diamond-SGC-iNEXT (DSI) Poised Library to enable fast and productive fragment-based lead discovery (FBLD).
-
Enamine Ltd. To Collaborate With EMBL For Cancer Drug Discovery Research
4/25/2017
-
Enamine Ltd. Release: Company Expands Collaboration With Europe’s Largest Biopharmaceutical Company
1/23/2017
-
Enamine Ltd. And Pcovery Extend Drug Discovery Collaboration
11/22/2016